From Nasdaq: 2025-04-01 12:47:00

GRI Bio, Inc. prices public offering at $3.60 per share, aiming to raise $5 million. Offering includes 1,388,888 shares of common stock with warrants exercisable at $3.20 per share. Expected to close on April 2, 2025, with H.C. Wainwright & Co. as placement agent. Proceeds will fund product development and corporate expenses. Interim safety results from Phase 2a study of GRI-0621 show trial’s continuation. Company secures two global patents for Natural Killer T cell modulators. GRI Bio regains Nasdaq compliance and stockholder approval for reverse stock split. Stock trading at $3.0501 on Nasdaq Capital Market, down 4.6844%.



Read more at Nasdaq: GRI Bio Announces $5 Million Public Offering Amid Market Decline